Camila Alves da Silva

Camila Alves da Silva

Auto-generated profile, based on publicly available information

Camila Alves da Silva

Ziel Biosciences

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
MLMartina Lichtenfels
Martina Lichtenfels
NLNoely Paula Cristina Lorenzi
Noely Paula Cristina Lorenzi
MTMaricy Tacla
Maricy Tacla
KYKaori Yokochi
Kaori Yokochi
FFFlávia Frustockl
Flávia Frustockl
CFCaroline Brunetto de Farias
Caroline Brunetto de Farias
Objective To evaluate the accuracy and patient acceptability toward self-sampling using a new device - SelfCervix® - for detecting HPV-DNA. Methods A total of 73 women aged 25–65 who underwent regular cervical cancer screening from March to October 2016 were included. Women performed self-sampling followed by a physician-sampling, and the samples were analyzed for HPV-DNA. After that, patients were surveyed about their acceptability of self-sampling. Results HPV-DNA detection rate of self-sampling presented high accuracy and was similar to physician-collection. Sixty-four (87.7%) patients answered the acceptability survey. Most patients (89%) considered the self-sampling comfortable, and 82.5% preferred self-sampling to physician-sampling. The reasons cited were time-saving and convenience. Fifty-one (79.7%) reported that they would recommend self-sampling. Conclusion Self-sampling using the new Brazilian device SelfCervix® is not inferior in HPV-DNA detection rate compared with physician-collection, and patients are supportive of the method. Therefore, it might be an option to reach under-screened populations in Brazil.

18 March 2025 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
MLMartina Lichtenfels
Martina Lichtenfels
RNRafaella Almeida Lima Nunes
Rafaella Almeida Lima Nunes
RLRossana Verónica Mendoza López
Rossana Verónica Mendoza López
CSCamila Alves da Silva
Camila Alves da Silva
LZLuiz Carlos Zeferino
Luiz Carlos Zeferino
LTLara Termini
Lara Termini
Objective: This study aimed to verify the relation between gastrin-releasing peptide receptor (GRPR), oncogenic Human Papillomavirus (HPV) and cervical lesions severity. Methods: GRPR mRNA levels were evaluated in cervical cancer-derived cell lines and in primary keratinocytes expressing HPV16 oncogenes by RT-PCR. GRPR protein expression was assessed by immunohistochemistry in organotypic cell cultures derived from […] Abstract Objective: This study aimed to verify the relation between gastrin-releasing peptide receptor (GRPR), oncogenic Human Papillomavirus (HPV) and cervical lesions severity. Methods: GRPR mRNA levels were evaluated in cervical cancer-derived cell lines and in primary keratinocytes expressing HPV16 oncogenes by RT-PCR. GRPR protein expression was assessed by immunohistochemistry in organotypic cell cultures derived from […]

16 July 2025 in Personalized Medicine
Verified
Journal Article
Closed access
MLMartina Lichtenfels
Martina Lichtenfels
MDMatheus G. S. Dalmolin
Matheus G. S. Dalmolin
JMJulia Caroline Marcolin
Julia Caroline Marcolin
HRHeloisa Resende
Heloisa Resende
ASAlessandra Borba Anton de Souza
Alessandra Borba Anton de Souza
JPJosé Luiz Pedrini
José Luiz Pedrini
Validate a novel in vitro resistance platform for breast cancer (BC) by assessing resistance profiles of treatment-naïve and residual tumors after neoadjuvant chemotherapy (NACT) and applying a machine learning algorithm to predict NACT response using clinical biomarkers. Tumor cells from primary BC and residual disease (RD) were cultured on the chemoresistance platform with various chemotherapies. Resistance was categorized as low ( < 40%), medium (40-60%), or high ( > 60%) after 72 h based on cell viability. Clinicopathological data from BC samples were analyzed using the XGBoost algorithm and SHAP interpretation to identify NACT-resistant patients. Patients undergoing upfront surgery (n = 70) exhibited significantly favorable prognosis compared to RD cases (n = 27), which had higher drug resistance and worse outcomes. AI analysis of 1,012 patients achieved 82% accuracy in predicting pathological response and RD, with age, estrogen receptor status, tumor grade and size, axillary status, and HER2 status identified as key predictors. The algorithm predicted NACT resistance with 81.8% accuracy in 11 patient samples. The chemoresistance platform identified resistance patterns highlighting its utility in precision medicine. Additionally, the XGBoost algorithm accurately predicted NACT response, supporting the integration of AI with functional precision medicine for personalized BC treatment.